Novartis Revolade shows long-term disease control for chronic/persistent immune thrombocytopenia
ZURICH: Novartis said on Wednesday a long-term study of its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) - a condition where patients’ blood does not clot normally.
Patients with ITP, which is caused by a low number of platelets, suffer bruising, bleeding and in some cases can even bleed to death.
The study showed platelet counts were elevated within two weeks of using Revolade treatment, with reduced overall bleeding, Novartis said.
(Reporting by John Revill)
bleedingdeathdisease controlimmune thrombocytopeniaITPlong-termNovartispharma newsplateletsrevoladesuffer bruising
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd